British regenerative medicine company Cell Therapy (CTL) has granted the Japanese licence for Heartcel, the company’s latest cardiac regeneration medicine, to Daiichi Sankyo.

Heartcel comprises immuno-modulatory progenitor (iMP) cells, a cardiac-specific cellular medicine.

On receiving the licence, the Japanese pharmaceutical company will be responsible for undertaking all regulatory, development and commercial activities for iMP cells within Japan.

However, Cell Therapy will retain all its global rights and manufacturing responsibilities outside of Japan.

"The accelerated regulatory pathway for regenerative medicines in Japan enables faster patient access, making it a natural priority for us."

Under the deal, Cell Therapy is to receive £12.5m as upfront licensing fee and additional milestone payments and royalties.

Cell Therapy chief executive officer Ajan Reginald said: "After a competitive process, we are delighted to partner with Daiichi Sankyo in Japan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The accelerated regulatory pathway for regenerative medicines in Japan enables faster patient access, making it a natural priority for us.

"This allows CTL to focus on the US and European Phase III trials and accelerating the development of our pre-clinical pipeline."

The Phase III trials for Heartcel are expected to commence later this year.

Nobel Laureate and Cell Therapy chief scientific officer Martin Evans said: "CTL’s in-house technology focusses on the discovery of novel tissue-specific cellular medicines.

"We are delighted that Daiichi Sankyo shares our belief in iMP cells’ potential in heart regeneration. This partnership is a validation of Cell Therapy’s novel approach and discovery technology."

iMP cells function as an advanced therapeutic medicinal product (ATMP) and investigational allogeneic regenerative medicine.